Product news

Share this article:
The FDA has broadened the US indication for Novartis' once-yearly Reclast (zoledronic acid) injection to include the prevention of new clinical fractures in patients who have recently had a low-trauma hip fracture.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M inVISION